RAPT Therapeutics
(NASDAQ:RAPT)
$4.10
0.06[1.49%]
At close: May 20
$4.10
0[0.00%]
PreMarket: 4:24AM EDT
Consensus Rating1
Neutral
Highest Price Target1
$0.00
Lowest Price Target1
$0.00
Consensus Price Target1
$23.83

RAPT Therapeutics Stock (NASDAQ:RAPT), Analyst Ratings, Price Targets, Predictions

RAPT Therapeutics Inc has a consensus price target of $23.83, established from looking at the 47 latest analyst ratings. The last 3 analyst ratings were released from Wolfe Research, Barclays, and Guggenheim on May 14, 2024, May 10, 2024, and May 10, 2024. With an average price target of $1.33 between Wolfe Research, Barclays, and Guggenheim, there's an implied -67.48% downside for RAPT Therapeutics Inc from these 3 analyst ratings.

Analyst Trend
1
Nov 23
3
5
Feb
1
Mar
1
Apr
2
May
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
3.3
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Wolfe Research
Barclays
Guggenheim
HC Wainwright & Co.
JP Morgan

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for RAPT Therapeutics

Buy NowGet Alert
05/14/2024Buy NowWolfe Research
Andy Chen
DowngradeOutperform → Peer PerformGet Alert
05/10/2024Buy Now-2.44%Barclays
Leon Wang
$13 → $4DowngradeOverweight → Equal-WeightGet Alert
05/10/2024Buy NowGuggenheim
Yatin Suneja
DowngradeBuy → NeutralGet Alert
04/10/2024Buy NowHC Wainwright & Co.
Raghuram Selvaraju
Reiterates → NeutralGet Alert
03/27/2024Buy Now217.07%JP Morgan
Anupam Rama
$15 → $13MaintainsNeutralGet Alert
02/22/2024Buy Now143.9%UBS
Eliana Merle
$61 → $10DowngradeBuy → NeutralGet Alert
02/21/2024Buy Now217.07%Barclays
Leon Wang
$35 → $13MaintainsOverweightGet Alert
02/21/2024Buy Now143.9%Leerink Partners
Thomas Smith
→ $10DowngradeOutperform → Market PerformGet Alert
02/21/2024Buy NowHC Wainwright & Co.
Raghuram Selvaraju
DowngradeBuy → NeutralGet Alert
02/21/2024Buy Now265.85%JP Morgan
Anupam Rama
$35 → $15DowngradeOverweight → NeutralGet Alert
02/20/2024Buy NowCantor Fitzgerald
Prakhar Agrawal
DowngradeOverweight → NeutralGet Alert
02/16/2024Buy NowEvercore ISI Group
Umer Raffat
Initiates → OutperformGet Alert
02/15/2024Buy Now851.22%Wolfe Research
Andy Chen
→ $39Initiates → OutperformGet Alert
11/30/2023Buy Now753.66%JP Morgan
Anupam Rama
$32 → $35MaintainsOverweightGet Alert
11/15/2023Buy Now900%HC Wainwright & Co.
Raghuram Selvaraju
→ $41ReiteratesBuy → BuyGet Alert
09/14/2023Buy Now729.27%Berenberg
Andy Chen
→ $34Initiates → BuyGet Alert
08/16/2023Buy Now680.49%JP Morgan
Anupam Rama
$39 → $32MaintainsOverweightGet Alert
08/14/2023Buy Now656.1%Piper Sandler
Edward Tenthoff
$28 → $31MaintainsOverweightGet Alert
08/14/2023Buy Now900%HC Wainwright & Co.
Raghuram Selvaraju
→ $41ReiteratesBuy → BuyGet Alert
08/09/2023Buy Now875.61%Stifel
Alex Thompson
→ $40Initiates → BuyGet Alert
06/15/2023Buy Now753.66%Barclays
Leon Wang
→ $35Initiates → OverweightGet Alert
06/05/2023Buy Now900%HC Wainwright & Co.
Raghuram Selvaraju
→ $41ReiteratesBuy → BuyGet Alert
05/12/2023Buy Now900%HC Wainwright & Co.
Raghuram Selvaraju
$43 → $41MaintainsBuyGet Alert
03/30/2023Buy Now948.78%HC Wainwright & Co.
Raghuram Selvaraju
→ $43Reiterates → BuyGet Alert
03/21/2023Buy Now924.39%JP Morgan
Anupam Rama
$48 → $42MaintainsOverweightGet Alert
03/21/2023Buy Now948.78%HC Wainwright & Co.
Raghuram Selvaraju
→ $43Reiterates → BuyGet Alert
03/15/2023Buy Now1070.73%Guggenheim
Yatin Suneja
$55 → $48MaintainsBuyGet Alert
03/15/2023Buy Now460.98%Goldman Sachs
Corinne Jenkins
$27 → $23MaintainsBuyGet Alert
03/15/2023Buy Now948.78%HC Wainwright & Co.
Raghuram Selvaraju
$50 → $43MaintainsBuyGet Alert
01/04/2023Buy Now1241.46%Guggenheim
Yatin Suneja
→ $55Initiates → BuyGet Alert

FAQ

Q

What is the target price for RAPT Therapeutics (RAPT)?

A

The latest price target for RAPT Therapeutics (NASDAQ: RAPT) was reported by Wolfe Research on May 14, 2024. The analyst firm set a price target for $0.00 expecting RAPT to fall to within 12 months (a possible -100.00% downside). 22 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for RAPT Therapeutics (RAPT)?

A

The latest analyst rating for RAPT Therapeutics (NASDAQ: RAPT) was provided by Wolfe Research, and RAPT Therapeutics downgraded their peer perform rating.

Q

When was the last upgrade for RAPT Therapeutics (RAPT)?

A

There is no last upgrade for RAPT Therapeutics.

Q

When was the last downgrade for RAPT Therapeutics (RAPT)?

A

The last downgrade for RAPT Therapeutics Inc happened on May 14, 2024 when Wolfe Research changed their price target from N/A to N/A for RAPT Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for RAPT Therapeutics (RAPT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of RAPT Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for RAPT Therapeutics was filed on May 14, 2024 so you should expect the next rating to be made available sometime around May 14, 2025.

Q

Is the Analyst Rating RAPT Therapeutics (RAPT) correct?

A

While ratings are subjective and will change, the latest RAPT Therapeutics (RAPT) rating was a downgraded with a price target of $0.00 to $0.00. The current price RAPT Therapeutics (RAPT) is trading at is $4.10, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch